ライフサイエンスコーパス: humoral rejection

1 might be effective in patients with 'chronic humoral rejection'.

2 estration of DSAs protects islet grafts from humoral rejection.

3 long graft survival times without immediate humoral rejection.

4 ular rejection with immunohistochemistry for humoral rejection.

5 ones from a kidney transplant recipient with humoral rejection.

6 et graft attrition, suggesting resistance to humoral rejection.

7 hat posttransplant capillaritis is a form of humoral rejection.

8 2 cases; the other nine had evidence only of humoral rejection.

9 d group antibody titers are at high risk for humoral rejection.

10 e endothelial deposition of C4d, a marker of humoral rejection.

11 lantation to elucidate the initial stages of humoral rejection.

12 lly reduced both DSAs and NDSAs and reversed humoral rejection.

13 ays an important role in initiation of acute humoral rejection.

14 jection, acute humoral rejection and chronic humoral rejection.

15 tion despite treatment with cyclosporine, or humoral rejection.

16 he interferon-gamma may reflect this ongoing humoral rejection.

17 ifficult barrier to organ transplantation is humoral rejection, a condition initiated by binding of a

18 Acute vascular or humoral rejection, a vexing outcome of organ transplanta

19 ficity of C4d staining as a marker for acute humoral rejection ACR in renal allografts, indirect immu

20 nts do not control the vigorous cellular and humoral rejection across species disparities.

21 anti-pig antibody leads to a delayed form of humoral rejection, acute humoral xenograft rejection, wh

22 .06-1.16; P < 0.001), severe vascular and/or humoral rejection (adjusted odds ratio, 1.06; 95% CI, 1.

23 (16.3 %) patients were diagnosed with acute humoral rejection (AHR) and 11/49 (22.4%) patients were

24 The distinction between acute humoral rejection (AHR) and acute cellular rejection (AC

25 Acute humoral rejection (AHR) has been associated with enhance

26 Standard therapy for acute humoral rejection (AHR) has been removal of donor-specif

27 The incidence of acute humoral rejection (AHR) in renal allograft biopsies has

28 Hyperacute rejection (HAR) and acute humoral rejection (AHR) remain recalcitrant conditions w

29 Acute humoral rejection (AHR), which occurs in up to 8% of kid

30 aft loss and the secondary outcome was acute humoral rejection (AHR).

31 donor-specific antibodies, a cause of acute humoral rejection (AHR).

32 opment of donor-specific alloantibody (acute humoral rejection, AHR) typically carries a poor prognos

33 entity that carries a poor prognosis (acute humoral rejection, AHR).

34 Acute humoral rejection, also known as acute vascular rejectio

35 for the newly appreciated conditions chronic humoral rejection and accommodation.

36 by B lymphocytes, which may lead to chronic humoral rejection and allograft failure.

37 hree categories: hyperacute rejection, acute humoral rejection and chronic humoral rejection.

38 cal pathways discriminate acute cellular and humoral rejection and DGF.

39 s, because they are strongly associated with humoral rejection and graft loss.

40 graft rejection, may be high at the time of humoral rejection and may not be elevated in cellular re

41 ent regimen tested here consistently prevent humoral rejection and systemic coagulation pathway dysre

42 eterioration include subclinical cellular or humoral rejection, and chronic calcineurin inhibitor tox

43 Sixteen animals showed humoral rejection, and in all but two animals one or mor

44 bulin G, had biopsy findings consistent with humoral rejection, and showed rapidly progressive xenogr

45 y understanding of the pathogenesis of acute humoral rejection, and to developing means of preventing

46 Current treatment options for humoral rejection are limited by a lack of specific anti

47 C4d is a specific marker for the presence of humoral rejection, as indicated by its association with

48 ably for 6 weeks and manifest no cellular or humoral rejection at that time.

49 There were no humoral rejections based on ABO-antigen-antibody interac

50 antibodies to function not only in classical humoral rejection but also as opsonins that facilitate t

51 in renal allograft recipients with 'chronic humoral rejection' by using an immunosuppressive regimen

52 In patients with biopsy-diagnosed humoral rejection (C4d+), serum levels of both DSA and N

53 Patients with humoral rejection can be identified with high sensitivit

54 The T2 average in humoral rejection cases (n=2) was 59.2+/-3.3 ms and the

55 he following histological diagnoses: chronic humoral rejection (CHR) (n=44), IF/TA (n=42), recurrence

56 eir transplant acutely but developed chronic humoral rejection (CHR) and in tolerant recipients (n =

57 Chronic humoral rejection (CHR) is a major complication after ki

58 Humoral rejection correlated with the baseline antibody

59 Further strategies to address humoral rejection could prolong graft survival and resul

60 ibodies are rarely detected, suggesting that humoral rejection does not play a significant role in co

61 t capillary-bound C4d is a robust marker for humoral rejection has started a new investigation into t

62 Most humoral rejection (HR) episodes occur early after cardia

63 usually either recurrent TMA (RecTMA) due to humoral rejection (HR-TMA) or due to calcineurin inhibit

64 ure (>20% increase in creatinine levels) and humoral rejection in graft pathology.

65 -type (WT) grafts showed hyperacute or acute humoral rejection in nonsensitized GalT KO mice with low

66 es did not correlate with the development of humoral rejection in the early posttransplant period.

67 te the physiologic role of DAF in preventing humoral rejection in the presence of low levels of NAb a

68 dies are consistent with a paradigm of acute humoral rejection in which CD4(+) T cell-dependent alloa

69 otection from infections, acute cellular and humoral rejections in patients with hypogammaglobulinemi

70 be a sensitive marker for antibody-mediated (humoral) rejection in renal transplant biopsies.

71 monstrating features consistent with delayed humoral rejection, including reactive vascular endotheli

72 Despite the recognition that humoral rejection is an important cause of allograft inj

73 Humoral rejection is associated with increased graft los

74 Evidence of acute cellular with occult humoral rejection is identified in more than 40% of late

75 Fortunately, humoral rejection is not the only outcome of antibody bi

76 Humoral rejection is the most common cause of solid orga

77 The hallmark of humoral rejection is the presence of subendothelial C4d

78 By 34 days, acute humoral rejection led to xenograft loss in all three xen

79 Late acute humoral rejection may be associated with interstitial he

80 Only one acute humoral rejection occurred 8 days after transplantation,

81 Humoral rejection occurred in 18% nonsplenectomized and

82 Humoral rejection occurred in one patient whereas acute

83 Irreversible humoral rejection occurred in one patient.

84 Humoral rejection occurs now more frequently in patients

85 However, humoral rejection of both DAF KO and DAF WT donor grafts

86 etic engineering of bone marrow may overcome humoral rejection of discordant xenografts and may be us

87 ng peritubular capillaries (PC) may indicate humoral rejection of renal allografts.

88 lso suggest that C4d in PTCs is specific for humoral rejection or, at least, for the presence of dono

89 prolonged graft survival, slowly progressive humoral rejection--probably associated with non-Gal anti

90 (> or =1:256) appear to be at high risk for humoral rejection regardless of protocol used.

91 mediated rejection, acute antibody-mediated (humoral) rejection, rejection mediated by the innate imm

92 r-old woman with hemodynamically significant humoral rejection resistant to steroids, cyclophos-phami

93 useful to prevent the vigorous cellular and humoral rejection response to xenografts.

94 be partially responsible for the absence of humoral rejection resulting from ABO-antigen-antibody in

95 recipients predisposed to acute cellular and humoral rejection, that is, children with intestinal tra

96 cognition is important in the development of humoral rejection; therefore, there is an increasing int

97 ith additional strategies aimed at silencing humoral rejection, VTL transplantation may significantly

98 or B-cell responses in recipients with acute humoral rejection, we sought to determine whether a simi

99 vascular lesions that can be associated with humoral rejection were not more frequent in the antibody

100 our renal allograft recipients with 'chronic humoral rejection' were prospectively identified.

101 This article reviews the features of humoral rejection, which we believe is responsible for m

102 Liver biopsies were routinely stained for humoral rejection with complement 4d (C4d) and for bilia

103 Donor organs showed progressive acute humoral rejection with deposits of IgM, IgG, and complem

104 was associated with the development of acute humoral rejection with features of coagulopathy.